Capasso Planning Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.08M Sell
4,979
-41
-0.8% -$9.1K 0.58% 25
2025
Q4
$1.15M Sell
5,020
-815
-14% -$186K 0.63% 24
2025
Q3
$1.35M Sell
5,835
-1,016
-15% -$207K 0.83% 22
2025
Q2
$1.27M Sell
6,851
-1,006
-13% -$187K 0.72% 24
2025
Q1
$1.65M Sell
7,857
-787
-9% -$153K 0.69% 29
2024
Q4
$1.54M Sell
8,644
-2,598
-23% -$478K 0.61% 33
2024
Q3
$2.22M Sell
11,242
-2,030
-15% -$379K 0.66% 29
2024
Q2
$2.28M Buy
13,272
+9,733
+275% +$1.61M 0.74% 31
2024
Q1
$645K Buy
3,539
+112
+3% +$19.3K 0.27% 52
2023
Q4
$531K Sell
3,427
-2
-0.1% -$292 0.25% 56
2023
Q3
$511K Sell
3,429
-39
-1% -$5.72K 0.27% 49
2023
Q2
$467K Buy
3,468
+52
+2% +$7.63K 0.25% 57
2023
Q1
$544K Buy
3,416
+72
+2% +$11K 0.32% 50
2022
Q4
$540K Buy
3,344
+115
+4% +$17.6K 0.34% 50
2022
Q3
$433K Sell
3,229
-9
-0.3% -$1.29K 0.3% 56
2022
Q2
$496K Buy
3,238
+71
+2% +$10.8K 0.35% 51
2022
Q1
$513K Hold
3,167
0.36% 47
2021
Q4
$429K Buy
+3,167
New +$374K 0.31% 53

Other funds holding ABBV

Capasso Planning Partners's ABBV Position: Q1 2026 in Review

Capasso Planning Partners reduced its AbbVie (ABBV) stake by 0.82% in Q1 2026, selling an estimated $9.1K and leaving 4,979 shares worth $1.08M. The position accounts for 0.58% of the portfolio, ranked #25.

Capasso Planning Partners first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.28M in Q2 2024. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Capasso Planning Partners held 4,979 shares of AbbVie worth $1.08M as of Q1 2026.
  • Capasso Planning Partners sold 41 AbbVie shares in Q1 2026, an estimated $9.1K.
  • AbbVie made up 0.58% of Capasso Planning Partners's portfolio in Q1 2026, its #25 holding.
  • Capasso Planning Partners first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • Capasso Planning Partners's AbbVie position peaked at $2.28M in Q2 2024.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Capasso Planning Partners's 13F filing for Q1 2026, filed 27 May 2026.